BIOMAT Database Logo BIOMAT Database Logo

Estrogen receptor-negative/progesterone receptor-positive and her-2-negative breast cancer might no longer be classified as hormone receptor-positive breast cancer. 2022

Hongjuan Zheng, and Chenyang Ge, and Haiping Lin, and Lunpo Wu, and Qinghua Wang, and Shishi Zhou, and Wanfen Tang, and Xia Zhang, and Xiayun Jin, and Xifeng Xu, and Zhongwu Hong, and Jianfei Fu, and Jinlin Du
Department of Medical Oncology, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, 351 Mingyue Road, Jinhua, 321000, Zhejiang Province, China.

BACKGROUND The single progesterone receptor (PR)-positive phenotype (estrogen receptor (ER)-/PR + , sPR positive) is an infrequent and independent biological entity. However, the prognosis of patients with sPR-positive and her-2-negative phenotype is still controversial, and it is not always easy to decide treatment strategies for them. METHODS Patients during 2010-2014 were identified from Surveillance, Epidemiology, and End Results (SEER) database. The Kaplan-Meier method was used to evaluate cancer-specific survival (CSS). The propensity score matching (PSM) method was used to balance differences of characteristics in groups. The Life-Table method was used to calculate 5-year CSS rates and the annual hazard rate of death (HRD). RESULTS A total of 97,527 patients were included, and only 745 (0.76%) patients were sPR-positive phenotype. The majority of sPR-positive breast cancer were basal-like subtype. Survival analysis showed that the sPR-positive breast cancer had similar prognosis comparing to double hormonal receptor-negative (ER-/PR-, dHoR-negative) breast cancer, and had the highest HRD during the initial 1-2 years of follow-up, then maintained the HRD of almost zero during the late years of follow-up. CONCLUSIONS The patients with sPR-positive and her-2-negative breast cancer, similar to dHoR-negative breast cancer, had a worse survival, and could benefit from chemotherapy significantly. However, the escalating endocrine therapy was not recommended for sPR-positive patients. The patients with sPR positive should be excluded from future clinical trials concerning endocrine therapy.

UI MeSH Term Description Entries
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D011960 Receptors, Estrogen Cytoplasmic proteins that bind estrogens and migrate to the nucleus where they regulate DNA transcription. Evaluation of the state of estrogen receptors in breast cancer patients has become clinically important. Estrogen Receptor,Estrogen Receptors,Estrogen Nuclear Receptor,Estrogen Receptor Type I,Estrogen Receptor Type II,Estrogen Receptors Type I,Estrogen Receptors Type II,Receptor, Estrogen Nuclear,Receptors, Estrogen, Type I,Receptors, Estrogen, Type II,Nuclear Receptor, Estrogen,Receptor, Estrogen
D011980 Receptors, Progesterone Specific proteins found in or on cells of progesterone target tissues that specifically combine with progesterone. The cytosol progesterone-receptor complex then associates with the nucleic acids to initiate protein synthesis. There are two kinds of progesterone receptors, A and B. Both are induced by estrogen and have short half-lives. Progesterone Receptors,Progestin Receptor,Progestin Receptors,Receptor, Progesterone,Receptors, Progestin,Progesterone Receptor,Receptor, Progestin
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D016019 Survival Analysis A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function. Analysis, Survival,Analyses, Survival,Survival Analyses
D018719 Receptor, ErbB-2 A cell surface protein-tyrosine kinase receptor that is overexpressed in a variety of ADENOCARCINOMAS. It has extensive homology to and heterodimerizes with the EGF RECEPTOR, the ERBB-3 RECEPTOR, and the ERBB-4 RECEPTOR. Activation of the erbB-2 receptor occurs through heterodimer formation with a ligand-bound erbB receptor family member. HER-2 Proto-Oncogene Protein,Proto-Oncogene Protein HER-2,Proto-Oncogene Protein p185(neu),c-erbB-2 Protein,erbB-2 Proto-Oncogene Protein,erbB-2 Receptor Protein-Tyrosine Kinase,neu Proto-Oncogene Protein,Antigens, CD340,CD340 Antigen,Erb-b2 Receptor Tyrosine Kinases,Metastatic Lymph Node Gene 19 Protein,Neu Receptor,Oncogene Protein HER-2,Proto-Oncogene Proteins c-erbB-2,Proto-oncogene Protein Neu,Receptor, Neu,Receptors, erbB-2,Tyrosine Kinase-type Cell Surface Receptor HER2,p185(c-neu),p185erbB2 Protein,CD340 Antigens,Erb b2 Receptor Tyrosine Kinases,ErbB-2 Receptor,HER 2 Proto Oncogene Protein,Oncogene Protein HER 2,Proto Oncogene Protein HER 2,Proto Oncogene Proteins c erbB 2,Proto-Oncogene Protein, HER-2,Proto-Oncogene Protein, erbB-2,Proto-Oncogene Protein, neu,Tyrosine Kinase type Cell Surface Receptor HER2,c erbB 2 Protein,erbB 2 Proto Oncogene Protein,erbB 2 Receptor Protein Tyrosine Kinase,erbB-2 Receptors,neu Proto Oncogene Protein
D064726 Triple Negative Breast Neoplasms Breast neoplasms that do not express ESTROGEN RECEPTORS; PROGESTERONE RECEPTORS; and do not overexpress the NEU RECEPTOR/HER-2 PROTO-ONCOGENE PROTEIN. ER-Negative PR-Negative HER2-Negative Breast Cancer,ER-Negative PR-Negative HER2-Negative Breast Neoplasms,Triple Negative Breast Cancer,Triple-Negative Breast Cancer,Triple-Negative Breast Neoplasm,Breast Cancer, Triple-Negative,Breast Cancers, Triple-Negative,Breast Neoplasm, Triple-Negative,Breast Neoplasms, Triple-Negative,ER Negative PR Negative HER2 Negative Breast Cancer,ER Negative PR Negative HER2 Negative Breast Neoplasms,Triple Negative Breast Neoplasm,Triple-Negative Breast Cancers,Triple-Negative Breast Neoplasms

Related Publications

Hongjuan Zheng, and Chenyang Ge, and Haiping Lin, and Lunpo Wu, and Qinghua Wang, and Shishi Zhou, and Wanfen Tang, and Xia Zhang, and Xiayun Jin, and Xifeng Xu, and Zhongwu Hong, and Jianfei Fu, and Jinlin Du
Should estrogen receptor positive and progesterone receptor negative and HER-2 negative breast cancer patients be considered as a luminal B subtype?
January 2020, Journal of B.U.ON. : official journal of the Balkan Union of Oncology,
Hongjuan Zheng, and Chenyang Ge, and Haiping Lin, and Lunpo Wu, and Qinghua Wang, and Shishi Zhou, and Wanfen Tang, and Xia Zhang, and Xiayun Jin, and Xifeng Xu, and Zhongwu Hong, and Jianfei Fu, and Jinlin Du
Immunohistochemical and clinicopathologic features of estrogen receptor-negative, progesterone receptor-positive, HER-2 negative breast carcinomas.
February 2021, Revista da Associacao Medica Brasileira (1992),
Hongjuan Zheng, and Chenyang Ge, and Haiping Lin, and Lunpo Wu, and Qinghua Wang, and Shishi Zhou, and Wanfen Tang, and Xia Zhang, and Xiayun Jin, and Xifeng Xu, and Zhongwu Hong, and Jianfei Fu, and Jinlin Du
Estrogen Receptor Positive and Progesterone Receptor Negative Breast Cancer: the Role of Hormone Therapy.
August 2020, Hormones & cancer,
Hongjuan Zheng, and Chenyang Ge, and Haiping Lin, and Lunpo Wu, and Qinghua Wang, and Shishi Zhou, and Wanfen Tang, and Xia Zhang, and Xiayun Jin, and Xifeng Xu, and Zhongwu Hong, and Jianfei Fu, and Jinlin Du
Prognostic Value of the Progesterone Receptor by Subtype in Patients with Estrogen Receptor-Positive, HER-2 Negative Breast Cancer.
February 2019, The oncologist,
Hongjuan Zheng, and Chenyang Ge, and Haiping Lin, and Lunpo Wu, and Qinghua Wang, and Shishi Zhou, and Wanfen Tang, and Xia Zhang, and Xiayun Jin, and Xifeng Xu, and Zhongwu Hong, and Jianfei Fu, and Jinlin Du
Characterization of estrogen receptor-negative/progesterone receptor-positive breast cancer.
November 2015, Human pathology,
Hongjuan Zheng, and Chenyang Ge, and Haiping Lin, and Lunpo Wu, and Qinghua Wang, and Shishi Zhou, and Wanfen Tang, and Xia Zhang, and Xiayun Jin, and Xifeng Xu, and Zhongwu Hong, and Jianfei Fu, and Jinlin Du
Outcomes of Estrogen Receptor Negative and Progesterone Receptor Positive Breast Cancer.
January 2015, PloS one,
Hongjuan Zheng, and Chenyang Ge, and Haiping Lin, and Lunpo Wu, and Qinghua Wang, and Shishi Zhou, and Wanfen Tang, and Xia Zhang, and Xiayun Jin, and Xifeng Xu, and Zhongwu Hong, and Jianfei Fu, and Jinlin Du
Natural history of estrogen receptor-negative, progesterone receptor-positive breast cancer.
January 2002, The International journal of biological markers,
Hongjuan Zheng, and Chenyang Ge, and Haiping Lin, and Lunpo Wu, and Qinghua Wang, and Shishi Zhou, and Wanfen Tang, and Xia Zhang, and Xiayun Jin, and Xifeng Xu, and Zhongwu Hong, and Jianfei Fu, and Jinlin Du
Multigene expression signatures in early hormone receptor positive HER 2 negative breast cancer.
September 2019, Radiology and oncology,
Hongjuan Zheng, and Chenyang Ge, and Haiping Lin, and Lunpo Wu, and Qinghua Wang, and Shishi Zhou, and Wanfen Tang, and Xia Zhang, and Xiayun Jin, and Xifeng Xu, and Zhongwu Hong, and Jianfei Fu, and Jinlin Du
Optimal regimen for treatment-naive hormone receptor-positive HER-2 negative metastatic breast cancer.
January 2019, Future oncology (London, England),
Hongjuan Zheng, and Chenyang Ge, and Haiping Lin, and Lunpo Wu, and Qinghua Wang, and Shishi Zhou, and Wanfen Tang, and Xia Zhang, and Xiayun Jin, and Xifeng Xu, and Zhongwu Hong, and Jianfei Fu, and Jinlin Du
Increased androgen receptor expression in estrogen receptor-positive/progesterone receptor-negative breast cancer.
February 2020, Breast cancer research and treatment,
Copied contents to your clipboard!